421 related articles for article (PubMed ID: 34453830)
1. Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine Among Actively Treated Cancer Patients.
Ligumsky H; Safadi E; Etan T; Vaknin N; Waller M; Croll A; Nikolaevski-Berlin A; Greenberg I; Halperin T; Wasserman A; Galazan L; Arber N; Wolf I
J Natl Cancer Inst; 2022 Feb; 114(2):203-209. PubMed ID: 34453830
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer.
Massarweh A; Eliakim-Raz N; Stemmer A; Levy-Barda A; Yust-Katz S; Zer A; Benouaich-Amiel A; Ben-Zvi H; Moskovits N; Brenner B; Bishara J; Yahav D; Tadmor B; Zaks T; Stemmer SM
JAMA Oncol; 2021 Aug; 7(8):1133-1140. PubMed ID: 34047765
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of the COVID-19 vaccine BNT162b2 in patients undergoing chemotherapy for solid cancer.
Funakoshi Y; Yakushijin K; Ohji G; Hojo W; Sakai H; Takai R; Nose T; Ohata S; Nagatani Y; Koyama T; Kitao A; Nishimura M; Imamura Y; Kiyota N; Harada K; Tanaka Y; Mori Y; Minami H
J Infect Chemother; 2022 Apr; 28(4):516-520. PubMed ID: 35090826
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of the mRNA-based BNT162b2 vaccine in systemic autoimmune rheumatic diseases patients.
Pri-Paz Basson Y; Tayer-Shifman OE; Naser R; Tartakover Matalon S; Kimhi O; Gepstein R; Halperin T; Ziv-Baran T; Ziv A; Parikh R; Kivity S; Levy Y
Clin Rheumatol; 2022 Dec; 41(12):3879-3885. PubMed ID: 36050514
[TBL] [Abstract][Full Text] [Related]
6. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
[TBL] [Abstract][Full Text] [Related]
7. Differences in Antibody Responses Between an Inactivated SARS-CoV-2 Vaccine and the BNT162b2 mRNA Vaccine in Solid-Organ Transplant Recipients.
Erol Ç; Yanık Yalçın T; Sarı N; Bayraktar N; Ayvazoğlu Soy E; Yavuz Çolak M; Azap Ö; Arslan H; Haberal M
Exp Clin Transplant; 2021 Dec; 19(12):1334-1340. PubMed ID: 34951350
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 Antibody Response to 2 or 3 Doses of the BNT162b2 Vaccine in Patients Treated With Anticancer Agents.
Fenioux C; Teixeira L; Fourati S; Melica G; Lelievre JD; Gallien S; Zalcman G; Pawlotsky JM; Tournigand C
JAMA Oncol; 2022 Apr; 8(4):612-617. PubMed ID: 34994776
[TBL] [Abstract][Full Text] [Related]
9. Effect of active anticancer therapy on serologic response to SARS-CoV-2 BNT162b2 vaccine in patients with urothelial and renal cell carcinoma.
Togashi K; Hatakeyama S; Yoneyama T; Hamaya T; Narita T; Fujita N; Iwamura H; Okamoto T; Yamamoto H; Yoneyama T; Hashimoto Y; Ohyama C
Int J Urol; 2022 Jul; 29(7):733-739. PubMed ID: 35362143
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of BNT162b2 vaccination in patients with solid cancer receiving anticancer therapy - a single centre prospective study.
Shmueli ES; Itay A; Margalit O; Berger R; Halperin S; Jurkowicz M; Levin EG; Levy I; Olmer L; Regev-Yochay G; Lustig Y; Rahav G
Eur J Cancer; 2021 Nov; 157():124-131. PubMed ID: 34508994
[TBL] [Abstract][Full Text] [Related]
11. Humoral response among patients with interstitial lung disease vaccinated with the BNT162b2 SARS-Cov-2 vaccine: a prospective cohort study.
Pertzov B; Shmueli E; Ben Zvi H; Massarweh A; Barkan T; Ness A; Shostak Y; Freidkin L; Shtraichman O; Kramer MR
Respir Res; 2022 Sep; 23(1):226. PubMed ID: 36045374
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients with primary brain tumors: a prospective cohort study.
Massarweh A; Tschernichovsky R; Stemmer A; Benouaich-Amiel A; Siegal T; Eliakim-Raz N; Stemmer SM; Yust-Katz S
J Neurooncol; 2022 Feb; 156(3):483-489. PubMed ID: 35018613
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine.
Kang YM; Minn D; Lim J; Lee KD; Jo DH; Choe KW; Kim MJ; Kim JM; Kim KN
J Korean Med Sci; 2021 Nov; 36(46):e311. PubMed ID: 34845875
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of COVID-19 vaccine in lung cancer patients receiving anticancer treatment: A prospective multicenter cohort study.
Nakashima K; Ishida M; Matsui H; Yoshida C; Nagai T; Shiraga M; Nakaoka H; Otsuka Y; Nakagama Y; Kaku N; Nitahara Y; Kido Y; Hirota Y
Hum Vaccin Immunother; 2022 Nov; 18(6):2140549. PubMed ID: 36369871
[TBL] [Abstract][Full Text] [Related]
15. [SARS-CoV2 anti-spike IgG response following COVID-19 mRNA vaccination (BNT162b2) in patients with hematological disorders].
Hagihara M; Sugi T; Uchida T; Ohara S; Imai Y; Inoue M; Mitamura K
Rinsho Ketsueki; 2022; 63(4):247-253. PubMed ID: 35491212
[TBL] [Abstract][Full Text] [Related]
16. Maternal-neonatal transfer of SARS-CoV-2 immunoglobulin G antibodies among parturient women treated with BNT162b2 messenger RNA vaccine during pregnancy.
Nir O; Schwartz A; Toussia-Cohen S; Leibovitch L; Strauss T; Asraf K; Doolman R; Sharabi S; Cohen C; Lustig Y; Regev-Yochay G; Yinon Y
Am J Obstet Gynecol MFM; 2022 Jan; 4(1):100492. PubMed ID: 34547533
[TBL] [Abstract][Full Text] [Related]
17. Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer.
Goshen-Lago T; Waldhorn I; Holland R; Szwarcwort-Cohen M; Reiner-Benaim A; Shachor-Meyouhas Y; Hussein K; Fahoum L; Baruch M; Peer A; Reiter Y; Almog R; Halberthal M; Ben-Aharon I
JAMA Oncol; 2021 Oct; 7(10):1507-1513. PubMed ID: 34236381
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis.
Yau K; Abe KT; Naimark D; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Mullin SI; Shadowitz E; Gonzalez A; Sukovic T; Garnham-Takaoka J; de Launay KQ; Takaoka A; Straus SE; McGeer AJ; Chan CT; Colwill K; Gingras AC; Hladunewich MA
JAMA Netw Open; 2021 Sep; 4(9):e2123622. PubMed ID: 34473256
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 Antibody Response After a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or Peritoneal Dialysis.
Bensouna I; Caudwell V; Kubab S; Acquaviva S; Pardon A; Vittoz N; Bozman DF; Hanafi L; Faucon AL; Housset P
Am J Kidney Dis; 2022 Feb; 79(2):185-192.e1. PubMed ID: 34508833
[TBL] [Abstract][Full Text] [Related]
20. A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study.
Lasagna A; Agustoni F; Percivalle E; Borgetto S; Paulet A; Comolli G; Sarasini A; Bergami F; Sammartino JC; Ferrari A; Zavaglio F; Arena F; Lilleri D; Secondino S; Falzoni M; Schiavo R; Klersy C; Lo Cascio G; Cavanna L; Baldanti F; Pedrazzoli P; Cassaniti I
ESMO Open; 2021 Oct; 6(5):100272. PubMed ID: 34543863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
